Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
- Conditions
- Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
- Interventions
- Drug: Placebo
- Registration Number
- NCT00160147
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 60
- Diagnosis of dementia of the Alzheimer's type
- History of seizure disorder
- Clinically significant electrocardiogram (ECG)
- Clinical or radiological evidence of stroke, vascular dementia or dementia due to substance abuse, or head trauma
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Placebo - 1 bifeprunox -
- Primary Outcome Measures
Name Time Method Brief Psychiatric Rating Scale (BPRS) Total Score 10 weeks
- Secondary Outcome Measures
Name Time Method Adverse events 10 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (51)
Site 912
🇺🇸Phoenix, Arizona, United States
Site 902
🇺🇸Carson, California, United States
Site 903
🇺🇸Long Beach, California, United States
Site 911
🇺🇸Pasadena, California, United States
Site 922
🇺🇸San Marino, California, United States
Site 910
🇺🇸Santa Ana, California, United States
Site 929
🇺🇸Hamden, Connecticut, United States
Site 914
🇺🇸New Britain, Connecticut, United States
Site 931
🇺🇸Norwalk, Connecticut, United States
Site 901
🇺🇸Miami, Florida, United States
Scroll for more (41 remaining)Site 912🇺🇸Phoenix, Arizona, United States